The Angelini Lumira Biosciences Fund will invest in early-stage companies in Canada and the US.

Angelini Pharma, part of the privately-owned Angelini holding company based in Italy, has set up its corporate venturing group with an initial $35m.

The Angelini Lumira Biosciences Fund (ALBF) will be managed by Lumira Ventures, a Canada-based life sciences-focused venture capital firm. Angelini Pharma has also committed $5m as a limited partner in Lumira Ventures IV, a $220m life sciences fund, announced last month.

ALBF will invest in early-stage companies in Canada and the US that are developing pharmaceutical therapies for central nervous system…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
James Mawson

James Mawson is founder and chief executive of Global Venturing.
Email LinkedIn